MAPT and dementia: When combined with the regular clinical workflow for suspected dementia, altered levels of plasma p-tau in patients with cognitive symptoms would point to potential AD (or at least AD-associated amyloidosis) while those with normal concentrations are further evaluated for non-AD causes of cognitive symptoms.